Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fertile women between age of 20 and 49~* Patients with cervical intraepithelial neoplasia 1(CIN1)~* HPV(Human Papilloma Virus) positive(+)~* White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 10\^6/L~* AST(Aspartate Aminotransferase) no less than 4 times higher than normal ALT(Alanine Aminotransferase) no less than 4 times higher than normal~* Normal for EKG(Electrocardiography) and no active disease detected trough chest X-ray~* Be informed of the nature of the study and will give written informed consent~Exclusion Criteria:~* Malignant tumor in any organ other than cervical intraepithelial neoplasia~* Active liver disease, immune disorder and severe renal failure~* Leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant allergic disease(mild allergic symptom not required medicine excluded)~* Diagnosed diabetes~* Taking any of followings affecting immunological reaction within 7 days (Glucocorticoid, vitamins, health food and oriental medicine etc)~* Pregnancy and breastfeeding~* Registered in other clinical trials~* Patients whom the investigator considers inappropriate to participate in the study

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Poly-gamma Glutamic Acid (Type: EXPERIMENTAL): Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).